Search

Your search keyword '"Luketich, James D"' showing total 1,744 results
Start Over Author "Luketich, James D"
1,744 results on '"Luketich, James D"'

309. Localized Intra-Cavitary Therapy to Drive Systemic Anti-Tumor Immunity.

Author

Donnenberg, Vera S., Wagner, Patrick L., Luketich, James D., Bartlett, David L., and Donnenberg, Albert D.

Subjects
IMMUNITY, PERITONEUM, CANCER invasiveness, EPITHELIAL-mesenchymal transition, CHEST endoscopic surgery
Abstract

Metastasis to the pleural and peritoneal cavities is a common terminal pathway for a wide variety of cancers. This article explores how these unique environments both promote aggressive tumor behavior and suppresses anti-tumor immunity, and ways in which local delivery of protein therapeutics can leverage the contained nature of these spaces to a therapeutic advantage, achieving high intra-cavital concentrations while minimizing systemic toxicity. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

310. Activity-Based Cost Analysis of Robotic Anatomic Lung Resection During Program Implementation.

Author

Coyan, Garrett N., Lu, Michael, Ruppert, Kristine M., Baker, Nicholas, Levy, Ryan M., Luketich, James D., Schuchert, Matthew J., and Sarkaria, Inderpal S.

Abstract

While robotic-assisted lung resection has seen a significant rise in adoption, concerns remain regarding initial programmatic outcomes and potential increased costs. We present our initial outcomes and cost analysis since initiation of a robotic lung resection program. Patients undergoing either video-assisted thoracoscopic lobectomy or segmentectomy (VATS) or robotic-assisted lobectomy or segmentectomy (RALS) between August of 2014 and January of 2017 underwent retrospective review. Patients underwent 1:1 propensity matching based on preoperative characteristics. Perioperative and 30-day outcomes were compared between groups. Detailed activity-based costing analysis was performed on individual patient encounters taking into effect direct and indirect controllable costs, including robotic operative supplies. There were no differences in 30-day mortality between RALS (n = 74) and VATS (n = 74) groups (0% vs 1.4%; P = 1). RALS patients had a decreased median length of stay (4 days vs 7 days; P <.001) and decreased median chest tube duration (3 days vs 5 days, P <.001). Total direct costs, including direct supply costs, were not significantly different between RALS and VATS ($6621 vs $6483; P =.784). Median total operating costs and total unit support costs, which are closely correlated to length of stay, were lower in the RALS group. Overall median controllable costs were significantly different between RALS and VATS ($16,352 vs $21,154; P =.025). A potentially cost-advantageous robotic-assisted pulmonary resection program can be initiated within the context of an existing minimally invasive thoracic surgery program while maintaining good clinical outcomes when compared with traditional VATS. Process-of-care changes associated with RALS may account for decreased costs in this setting. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

338. The ideal approach for treatment of cT1N+ and cT2Nany esophageal cancer.: a NCDB analysis.

Author

Huang, Binhao, Chan, Ernest G., Pennathur, Arjun, Luketich, James D., and Zhang, Jie

Subjects
ESOPHAGEAL cancer, NEOADJUVANT chemotherapy, TUMOR classification, SQUAMOUS cell carcinoma, ONCOLOGIC surgery, ADENOCARCINOMA, ADJUVANT chemotherapy
Abstract

Background: Neoadjuvant therapy followed by surgery is recommended for locally advanced esophageal cancer. With the inaccuracies of clinical staging particularly for cT1N+ and cT2Nany tumors, some have proposed consideration of surgery followed by adjuvant treatment. Our objective is to evaluate the efficacy of neoadjuvant therapy vs surgery followed by adjuvant therapy, and to identify the ideal sequence of treatment in patients with cT1N+ and cT2Nany tumors.Methods: We performed an analysis utilizing the National Cancer Database (2006-2015) identifying all patients with cT1N+ and cT2Nany esophageal cancer undergoing esophagectomy. The treatment was stratified as: neoadjuvant therapy (NT), adjuvant therapy (AT) and combination therapy of neoadjuvant and adjuvant (CT) groups and outcomes were analyzed.Results: We identified 2795 patients with 81.9% (n=2289) receiving NT, 10.2% (n=285) AT, and 7.9% (n=221) CT. There were no significant differences noted in survival among AT, NT, and CT group in cT1N+(P=0.376), cT2N-(P=0.436), cT2N+(P=0.261) esophageal cancer by multivariate analysis using Cox regression model. This relationship held true in both squamous cell carcinoma and adenocarcinoma.Conclusion: In clinical T1N+, T2Nany patients, there was no evident superiority of NT over AT. Surgery followed by adjuvant therapy can be considered to be an alternative option in these patients. Further prospective studies are needed to validate these findings. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

344. Elevated hepatocyte growth factor level correlates with poor outcome in early-stage and late-stage adenocarcinoma of the lung *

Author

Sieffried, Jill M., Luketich, James D., Stabile, Laura P., Christie, Nell, and Land, Stephanie R.

Subjects
Survival after airplane accidents, shipwrecks, etc. -- Research -- Statistics, Adenocarcinoma -- Research, Lung cancer -- Research, Health, Statistics, Research
Abstract

Abbreviations: HGF = hepatocyte growth factor; NED = no evidence of disease The 5-year survival rate for patients with air stages of lung cancer combined is only 15%. The survival [...]

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results